Erythropoietin (EPO) support during radiation therapy had no impact on outcomes in patients with head and neck squamous-cell carcinoma (HNSCC) and mild or moderate anemia, long-term results of a randomized trial showed. Locoregional failure, locoregional progression-free survival (PFS), and overall survival (OS) did not differ significantly between patients who received concomitant EPO and those who […]

by

A cannabis derivative could help children with epilepsy, according to a series of studies presented at the American Epilepsy Society’s 69th Annual Meeting in Philadelphia, PA. A cannabis derivative appears to help prevent seizures. Cannabidiol (CBD), a type of cannabinoid, has come into focus as a potential therapy for various conditions, including epilepsy. CBD is […]

by

March 14, 2016 Cannabidiol Therapy Reduces Seizure Frequency in Dravet Syndrome Investigators have announced positive results for the first phase 3 clinical trial of GW Pharmaceutical’s cannabidiol therapy Epidiolex in patients with Dravet syndrome. The unpublished results mark a milestone for Epidiolex, which has already received Orphan Drug Designation and Fast Track Designation from the […]

by

WASHINGTON, March 14 (UPI) — The marijuana-based drug Epidiolex significantly reduced seizures in children with Dravet syndrome in a phase 3 clinical trial, lending scientific credence to a treatment used for several years but mostly supported by anecdotal evidence. GW Pharmaceuticals, which developed the drug, announced the results of the first of four trials with […]

by

Biopharmaceutical company GW Pharmaceuticals announced Monday positive results of its Phase 3 pivotal study for cannabidiol (CBD) treatment, Epidiolex, for the treatment of severe forms of epilepsy. Epidiolex is a liquid formulation of CDB, which is the most abundant non-psychoactive cannabinoid in the marijuana plant. “The results of this Epidiolex pivotal trial are important and […]

by

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, […]

by

Shares of Cannabis Sativa Inc (OTCMKTS:CBDS) exploded up the charts on the back of positive news from GW Pharmaceuticals plc (NASDAQ:GWPH). GWPH announced positive results in a Phase 3 clinical trial assessing Orphan Drug- and Fast Track-tagged Epidiolex (cannabidiol) for the treatment of Dravet syndrome, a rare and catastrophic form of childhood epilepsy for which there are no […]

by

The FDA designates Zynerba Pharmaceuticals’ (ZYNE +2%) ZYN002 cannabidiol gel an Orphan Drug for the treatment of Fragile X syndrome, a genetic disorder characterized by learning disabilities and cognitive impairment. ZYN002 is designed to deliver a controlled dose of cannabidiol transdermally via a permeation-enhanced gel formulation. A Phase 2 study should commence by year end. […]

by

TYLER, TX — (Marketwired) — 02/24/16 — Wisdom Homes of America, Inc. (the “Company”) (OTC PINK: WOFA) concentrates on licensing products and technology benefiting the cannabis patient and consumers. The Company is proud to announce that it has contracted with Healthy Asylum, Inc., a manufacturer of oral strips including CannaStrips. Healthy Asylum has completed an […]

by

PHILADELPHIA — In the largest study of its kind, researchers report that Epidiolex, a pharmaceutical-grade, purified form of cannabidiol, is generally well-tolerated and is a promising treatment for treatment-resistant epilepsies. The results, from the open-label Expanded Access treatment programs from 16 sites, were presented at the 2015 American Epilepsy Society Annual Meeting in Philadelphia. Epidiolex, […]

by